iRadimed Corporation (NASDAQ:IRMD) Receives Average Rating of “Buy” from Analysts

Shares of iRadimed Corporation (NASDAQ:IRMD) have been given an average recommendation of “Buy” by the five ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $120.00.

A number of research analysts have recently commented on the stock. Lake Street Capital reissued a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a research report on Wednesday, February 11th. Weiss Ratings downgraded shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, May 20th. Roth Mkm reaffirmed a “buy” rating and set a $120.00 target price on shares of iRadimed in a report on Tuesday, February 10th. Finally, Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd.

iRadimed Price Performance

Shares of IRMD opened at $92.94 on Wednesday. The firm has a 50-day moving average of $92.46 and a 200-day moving average of $95.28. iRadimed has a one year low of $51.26 and a one year high of $107.90. The company has a market cap of $1.19 billion, a PE ratio of 50.79 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last announced its quarterly earnings data on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. The company had revenue of $21.98 million during the quarter, compared to the consensus estimate of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Analysts expect that iRadimed will post 1.52 earnings per share for the current year.

iRadimed Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 29th. Investors of record on Friday, May 15th will be issued a dividend of $0.20 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. iRadimed’s payout ratio is presently 43.72%.

Insider Activity at iRadimed

In related news, CEO Roger E. Susi sold 2,500 shares of iRadimed stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $87.88, for a total transaction of $219,700.00. Following the completion of the sale, the chief executive officer owned 2,172,500 shares of the company’s stock, valued at approximately $190,919,300. The trade was a 0.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 67,500 shares of company stock worth $6,318,853. Insiders own 36.80% of the company’s stock.

Institutional Trading of iRadimed

Several hedge funds and other institutional investors have recently modified their holdings of IRMD. CWM LLC boosted its holdings in iRadimed by 19.5% in the 4th quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock valued at $64,000 after purchasing an additional 107 shares during the period. Johnson Investment Counsel Inc. raised its position in shares of iRadimed by 0.7% in the 3rd quarter. Johnson Investment Counsel Inc. now owns 25,842 shares of the medical equipment provider’s stock valued at $1,839,000 after buying an additional 187 shares in the last quarter. Summit Global Investments raised its position in shares of iRadimed by 2.7% in the 3rd quarter. Summit Global Investments now owns 7,139 shares of the medical equipment provider’s stock valued at $508,000 after buying an additional 188 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of iRadimed by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock valued at $252,000 after buying an additional 234 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of iRadimed by 4.8% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,824 shares of the medical equipment provider’s stock valued at $567,000 after buying an additional 267 shares in the last quarter. Institutional investors own 92.34% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.